BioSpace News Archive

Specialty diagnostics company Precipio, Inc., announced that it has regained compliance with the Nasdaq listing requirements.

New COVID-19 case projections released by PolicyLab at Children’s Hospital of Philadelphia paint a sobering picture for much of the United States over the next four weeks—forecasting significant continued virus resurgence in known hotspots such as Houston and Miami and rising risk once again in communities across the Mid-Atlantic and Midwest.

Gravity Diagnostics, a CLIA laboratory headquartered in Covington, Kentucky, today announced the U.S. Food and Drug Administration (FDA) has granted an update to their Emergency Use Authorization (EUA) to include use of nasal swab specimens that are self-collected by individuals using the Kroger Health COVID-19 Test Home Collection Kit.

FibroGenesis announced today identification of molecular mechanisms associated with the potent reduction of lung inflammation previously reported by the Company in an animal model of COVID-19 lung failure.

Align Technology, Inc. (Nasdaq: ALGN) announced today that the Company will report second quarter 2020 financial results on Wednesday, July 22, 2020, after the close of market.

Venus Concept Inc. announced that it has received FDA 510 clearance to market and sell Venus Viva MD. Venus Viva MD is a non-invasive device intended to be used by aesthetic-related physicians or dermatologists.

Cytokinetics, Incorporated (Nasdaq: CYTK), today announced that it will host a Virtual Investor and Analyst Day on Wednesday, July 15, 2020 from 8:30 AM to 11:30 AM ET.

BioLife Solutions, Inc. (NASDAQ: BLFS) (“BioLife” or the “Company”), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today announced it intends to offer shares of its common stock for sale in an underwritten public offering.

SmileDirectClub, Inc., the first direct-to-consumer telehealth platform for teeth straightening, announced its continued international expansion with openings in Singapore and Austria.

Context Therapeutics LLC, a clinical-stage biopharmaceutical company dedicated to advancing medicines for hormone driven cancers, today announced that results from a safety review from preclinical and two Phase 1-2 studies evaluating its drug candidate onapristone extended release (ONA-ER) for the treatment of progesterone receptor (PR) positive cancers has been published in the journal Drug Safety.